ClinicalTrials.Veeva

Menu

Proteomics of Papillary Thyroid Carcinoma

I

Inner Mongolia Medical University

Status

Enrolling

Conditions

Papillary Thyroid Carcinoma

Study type

Observational

Funder types

Other

Identifiers

NCT02814032
AHInnerMongolia-Thyroid-02

Details and patient eligibility

About

Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid carcinoma patients. This study aim to reveal protein expression differences between papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis.

Full description

  1. Object: Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer.
  2. Clinical information, examination data: Information is obtained from medical record abstraction.
  3. Samples: Fresh frozen thyroid tissues from each sample group(normal histology, benign disease, papillary thyroid carcinoma with cervical lymph node metastasis, papillary thyroid carcinoma without cervical lymph node metastasis ).

Enrollment

32 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Newly diagnosed papillary thyroid carcinoma.
  • Undergo thyroidectomy according to the China thyroid association guidelines forthe Management of thyroid nodule and thyroid cancer.

Exclusion criteria

  • Current substance abuse/dependence.
  • Daily tobacco and alcohol use.
  • Whole neck irradiation or surgery.
  • Prior cancer diagnosis or chemotherapy treatment.
  • Active autoimmune disorder.
  • Uncontrolled allergic condition or asthma.
  • Chronic use of oral steroid medication.
  • Hormone therapy (estrogen, progestin compounds).

Trial design

32 participants in 4 patient groups

PTC group 1
Description:
papillary thyroid carcinoma patients with cervical lymph node metastasis
PTC group 2
Description:
papillary thyroid carcinoma patients without cervical lymph node metastasis
Positive control group
Description:
benign disease
Negative control group
Description:
histologically normal

Trial contacts and locations

1

Loading...

Central trial contact

Yun-tian Yang, PhD; Shan Jin, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems